Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gray (Gy) each than following two, 9-Gy fractions of high-dose-rate (HDR) brachytherapy, but neither overall survival nor severe treatment-related side effects differed between the treatment groups.

October 4, 2017 — Kubtec announced at the annual conference of the American Association of Pathology Assistants (AAPA) that they are expanding their proprietary use of 3-D tomosynthesis by bringing it to the XPERT 80 Specimen X-ray System. Kubtec introduced 3-D imaging for clinical specimens with the Mozart System, the first specimen X-ray system to use 3-D tomosynthesis, according to the company. 
 

In the 1980s I was enthralled with hybridomas. Created by fusing human tumor cells with cells from mouse spleens that had been sensitized to the patient’s own cancer, they were supposed to pump out the magic bullets that finally would take cancer down. At the time, I believed it.

Thirty years later, the jury is still out.

Immune technology is taking some impressive steps. But it has not lived up to early expectations.

The Siemens Acuson
GE Invenia ABUS
Hitachi Sofia With Arietta 70
The SonoCiné automated whole breast ultrasound (AWBUS)

According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent compound annual growth rate (CAGR) from 2017-2024, driven by rising incidence of breast cancer and volume scanner segment dominating this growth.
Why guidelines aren't just for patients

Over the years, significant progress has been made educating women, men and families about breast cancer — the pink ribbon has become the universal symbol of breast health and awareness, and more women than ever before know about the disease, the risks it poses and the necessary steps to take to prevent and detect it early.
As healthcare facilities move to value-based care, they need to be able to rely on their healthcare technology partner

In an era of population health consciousness and uncertainty regarding regulations, healthcare facilities need to be able to rely on technology as a constant in a sea of change. As healthcare facilities move to value-based care, they need to be able to rely on their healthcare technology partner. This extends beyond the initial equipment investment to continued service and support. The service and support a partner provides after the sale can be more important than the sale itself.
Growing emergence of electronic devices in the medical sector to maintain electronic records of patients will stimulate the healthcare analytics industry

The healthcare analytics market is witnessing a phenomenon of sorts, with an increasing number of remote consultations and monitoring practices across the globe. The surging adoption of smartphones and tablets will favorably attribute the product demand across a myriad of medical application arenas such as financial, clinical and operations management. 
Trends in contrast media used in magnetic resonance imaging and computed tomography

Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast agents accumulate in tissues inside patients. This has raised concern because prolonged, elevated levels of gadolinium in the body may cause a nephrogenic systemic fibrosis in patients with severe kidney disease. Adding to this concern were three studies in 2015, which raised new gadolinium safety concerns after it was found the agent also accumulates in the brain

October 3, 2017 — Healthcare information technology (IT) experts at Logicalis Healthcare Solutions say in a new whitepaper that now is the time for healthcare organizations to develop IT cloud strategies for deployment of critical patient care applications and provider administrative systems. The paper identifies five reasons why healthcare providers need a strong cloud strategy now for employees, partners and patients (also the title of the paper).

A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to radiation therapy, as well as their likelihood of disease recurrence and survival outcomes. The analysis of more than 9,000 prostate tumors also found evidence that PD-L2, not PD-L1, may provide a key route for targeted therapies, such as immunotherapy, to slow disease progression. Findings were presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now